{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:56:01Z","timestamp":1791860161064,"version":"4.3.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2015,3,27]],"date-time":"2015-03-27T00:00:00Z","timestamp":1427414400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s00277-015-2314-2","type":"journal-article","created":{"date-parts":[[2015,3,26]],"date-time":"2015-03-26T11:33:30Z","timestamp":1427369610000},"page":"241-247","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":192,"title":["Epidemiology of chronic myeloid leukaemia: an update"],"prefix":"10.1007","volume":"94","author":[{"given":"Martin","family":"H\u00f6glund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Sandin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Simonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,27]]},"reference":[{"key":"2314_CR1","unstructured":"Socialstyrelsen (2009) Cancer incidence in Sweden. www.socialstyrelsense\/publikationer1999\/1999-42-8"},{"issue":"5","key":"2314_CR2","first-page":"535","volume":"44","author":"HH Storm","year":"1997","unstructured":"Storm HH, Michelsen EV, Clemmensen IH, Pihl J (1997) The Danish Cancer Registry\u2014history, content, quality and use. Dan Med Bull 44(5):535\u2013539","journal-title":"Dan Med Bull"},{"issue":"5","key":"2314_CR3","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2141.2009.08010.x","volume":"148","author":"A Smith","year":"2010","unstructured":"Smith A, Roman E, Howell D, Jones R, Patmore R, Jack A, Haematological Malignancy Research N (2010) The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research. Br J Haematol 148(5):739\u2013753. doi: 10.1111\/j.1365-2141.2009.08010.x","journal-title":"Br J Haematol"},{"issue":"10","key":"2314_CR4","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1002\/ijc.22912","volume":"121","author":"I Turesson","year":"2007","unstructured":"Turesson I, Linet MS, Bjorkholm M, Kristinsson SY, Goldin LR, Caporaso NE, Landgren O (2007) Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer 121(10):2260\u20132266. doi: 10.1002\/ijc.22912","journal-title":"Int J Cancer"},{"key":"2314_CR5","unstructured":"http:\/\/seer.cancer.gov (2014) SEER. Cancer statistics review 1975-2011."},{"issue":"16","key":"2314_CR6","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1182\/blood-2011-01-330332","volume":"118","author":"S Corm","year":"2011","unstructured":"Corm S, Roche L, Micol JB, Coiteux V, Bossard N, Nicolini FE, Iwaz J, Preudhomme C, Roche-Lestienne C, Facon T, Remontet L (2011) Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study. Blood 118(16):4331\u20134337. doi: 10.1182\/blood-2011-01-330332","journal-title":"Blood"},{"issue":"3","key":"2314_CR7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/003693300404900305","volume":"49","author":"SJ Harrison","year":"2004","unstructured":"Harrison SJ, Johnson PR, Holyoake TL (2004) The Scotland Leukaemia Registry audit of incidence, diagnosis and clinical management of new patients with chronic myeloid leukaemia in 1999 and 2000. Scott Med J 49(3):87\u201390","journal-title":"Scott Med J"},{"issue":"7","key":"2314_CR8","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood-2013-04-495598","volume":"122","author":"M H\u00f6glund","year":"2013","unstructured":"H\u00f6glund M, Sandin F, Hellstrom K, Bjoreman M, Bjorkholm M, Brune M, Dreimane A, Ekblom M, Lehmann S, Ljungman P, Malm C, Markevarn B, Myhr-Eriksson K, Ohm L, Olsson-Stromberg U, Sjalander A, Wadenvik H, Simonsson B, Stenke L, Richter J (2013) Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood 122(7):1284\u20131292. doi: 10.1182\/blood-2013-04-495598","journal-title":"Blood"},{"issue":"1","key":"2314_CR9","doi-asserted-by":"crossref","first-page":"e004266","DOI":"10.1136\/bmjopen-2013-004266","volume":"4","author":"AG Smith","year":"2014","unstructured":"Smith AG, Painter D, Howell DA, Evans P, Smith G, Patmore R, Jack A, Roman E (2014) Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort. BMJ Open 4(1):e004266. doi: 10.1136\/bmjopen-2013-004266","journal-title":"BMJ Open"},{"key":"2314_CR10","unstructured":"Lindoerfer D, Pfirrmann M, Saussele S, Hochhaus A, Engel J, Guilhot J, Rosti G, Mayer J, Indrak K, Castagnetti F, Turkina A, Zaritskey A, Steegmann JL, Hellmann A, Thielen N, Cervantes F, Simonsson B, Colita A, Clark RE, Almeida A, Labar B, Marin D, Ossenkoppele GJ, Bogdanovic A, Dyagil I, Porkka K, O\u2019Brien S, Griskevicius L, Panagiotidis P, Thaler J, Zupan I, Lejniece S, Everaus H, Masszi T, Melanthiou F, Hehlmann R, Hasford J, Baccarani M (2013) CML patients in clinical trials represent fairly well the general population of CML patients: a comparative analysis of 5803 patients from the EUTOS Registry, vol 122. vol 21"},{"issue":"17","key":"2314_CR11","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1182\/blood-2011-12-379008","volume":"119","author":"G Juliusson","year":"2012","unstructured":"Juliusson G, Lazarevic V, Horstedt AS, Hagberg O, Hoglund M (2012) Acute myeloid leukemia in the real world: why population-based registries are needed. Blood 119(17):3890\u20133899. doi: 10.1182\/blood-2011-12-379008","journal-title":"Blood"},{"issue":"4","key":"2314_CR12","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/thx.2009.125914","volume":"65","author":"A Berglund","year":"2010","unstructured":"Berglund A, Holmberg L, Tishelman C, Wagenius G, Eaker S, Lambe M (2010) Social inequalities in non-small cell lung cancer management and survival: a population-based study in central Sweden. Thorax 65(4):327\u2013333. doi: 10.1136\/thx.2009.125914","journal-title":"Thorax"},{"issue":"3","key":"2314_CR13","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1182\/blood-2013-05-501312","volume":"122","author":"M Bjorkholm","year":"2013","unstructured":"Bjorkholm M, Kristinsson SY, Landgren O, Goldin LR (2013) No familial aggregation in chronic myeloid leukemia. Blood 122(3):460\u2013461. doi: 10.1182\/blood-2013-05-501312","journal-title":"Blood"},{"issue":"6","key":"2314_CR14","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.ahj.2006.07.028","volume":"152","author":"R Carlhed","year":"2006","unstructured":"Carlhed R, Bojestig M, Wallentin L, Lindstrom G, Peterson A, Aberg C, Lindahl B (2006) Improved adherence to Swedish national guidelines for acute myocardial infarction: the Quality Improvement in Coronary Care (QUICC) study. Am Heart J 152(6):1175\u20131181. doi: 10.1016\/j.ahj.2006.07.028","journal-title":"Am Heart J"},{"key":"2314_CR15","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/1471-2407-9-252","volume":"9","author":"F Bhayat","year":"2009","unstructured":"Bhayat F, Das-Gupta E, Smith C, McKeever T, Hubbard R (2009) The incidence of and mortality from leukaemias in the UK: a general population-based study. BMC Cancer 9:252. doi: 10.1186\/1471-2407-9-252","journal-title":"BMC Cancer"},{"issue":"5","key":"2314_CR16","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1016\/j.leukres.2010.12.034","volume":"35","author":"CS Chang","year":"2011","unstructured":"Chang CS, Lee K, Yang YH, Lin MT, Hsu CN (2011) Estimation of CML incidence: disagreement between national cancer registry and health claims data system in Taiwan. Leuk Res 35(5):e53\u2013e54. doi: 10.1016\/j.leukres.2010.12.034","journal-title":"Leuk Res"},{"issue":"7","key":"2314_CR17","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.3109\/10428194.2012.745525","volume":"54","author":"Y Chen","year":"2013","unstructured":"Chen Y, Wang H, Kantarjian H, Cortes J (2013) Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. Leuk Lymphoma 54(7):1411\u20131417. doi: 10.3109\/10428194.2012.745525","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2314_CR18","first-page":"2964","volume":"110","author":"J Hasford","year":"2007","unstructured":"Hasford J, Tauscher M, Hochhaus A (2007) Incidence, comorbidity and treatment survey of chronic myeloid leukemia in Germany. ASH Ann Meet Abstr 110(11):2964","journal-title":"ASH Ann Meet Abstr"},{"issue":"3","key":"2314_CR19","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/leu.2008.245","volume":"23","author":"M Rohrbacher","year":"2009","unstructured":"Rohrbacher M, Berger U, Hochhaus A, Metzgeroth G, Adam K, Lahaye T, Saussele S, Muller MC, Hasford J, Heimpel H, Hehlmann R (2009) Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph\/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 23(3):602\u2013604. doi: 10.1038\/leu.2008.245","journal-title":"Leukemia"},{"issue":"3","key":"2314_CR20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.beha.2009.07.007","volume":"22","author":"M Rohrbacher","year":"2009","unstructured":"Rohrbacher M, Hasford J (2009) Epidemiology of chronic myeloid leukaemia (CML). Best Pract Res Clin Haematol 22(3):295\u2013302. doi: 10.1016\/j.beha.2009.07.007","journal-title":"Best Pract Res Clin Haematol"},{"issue":"17","key":"2314_CR21","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1016\/j.ejca.2012.05.024","volume":"48","author":"O Visser","year":"2012","unstructured":"Visser O, Trama A, Maynadie M, Stiller C, Marcos-Gragera R, De Angelis R, Mallone S, Tereanu C, Allemani C, Ricardi U, Schouten HC, Group RW (2012) Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer 48(17):3257\u20133266. doi: 10.1016\/j.ejca.2012.05.024","journal-title":"Eur J Cancer"},{"issue":"8","key":"2314_CR22","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0145-2126(00)00038-2","volume":"24","author":"RP Gale","year":"2000","unstructured":"Gale RP, Cozen W, Goodman MT, Wang FF, Bernstein L (2000) Decreased chronic lymphocytic leukemia incidence in Asians in Los Angeles County. Leuk Res 24(8):665\u2013669","journal-title":"Leuk Res"},{"issue":"4","key":"2314_CR23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/00008469-200608000-00011","volume":"15","author":"MJ Matasar","year":"2006","unstructured":"Matasar MJ, Ritchie EK, Consedine N, Magai C, Neugut AI (2006) Incidence rates of acute promyelocytic leukemia among Hispanics, blacks, Asians, and non-Hispanic whites in the United States. Eur J Cancer Prev 15(4):367\u2013370","journal-title":"Eur J Cancer Prev"},{"issue":"11","key":"2314_CR24","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.leukres.2010.03.033","volume":"34","author":"DW Kim","year":"2010","unstructured":"Kim DW, Banavali SD, Bunworasate U, Goh YT, Ganly P, Huang H, Irving I, Jootar S, Goh HG, Koh LP, Li W, Naoe T, Ng SC, Purushotaman V, Reksodiputro H, Shih LY, Tang JL, Tojo A, Wang J, Wong R (2010) Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era. Leuk Res 34(11):1459\u20131471. doi: 10.1016\/j.leukres.2010.03.033","journal-title":"Leuk Res"},{"key":"2314_CR25","unstructured":"Hoffmann V, Lindoerfer D, Thaler J, Labar B, Melanthiou F, Mayer J, Everaus H, Porkka K, Guilhot F, Schubert-Fritschle G, Castagnetti F, Lejniece S, Griskevicius L, Thielen N, Hellmann A, Turkina A, Zaritskey A, Bogdanovic A, Indrak K, Zupan I, Casado L-F, Simonsson B, Clark RE, Hehlmann R, Hasford J, Baccarani M (2014) The EUTOS population based registry\u2014incidences of CML across Europe. European Hematology Association Annual Meeting 2014"},{"issue":"1","key":"2314_CR26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/bjh.12977","volume":"167","author":"J Fuente de la","year":"2014","unstructured":"de la Fuente J, Baruchel A, Biondi A, de Bont E, Dresse MF, Suttorp M, Millot F, International BFMGSGCMLC (2014) Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18\u00a0years. Br J Haematol 167(1):33\u201347. doi: 10.1111\/bjh.12977","journal-title":"Br J Haematol"},{"issue":"6","key":"2314_CR27","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/sj.leu.2403756","volume":"19","author":"U Berger","year":"2005","unstructured":"Berger U, Maywald O, Pfirrmann M, Lahaye T, Hochhaus A, Reiter A, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Loffler H, Pralle H, Queisser W, Hehlmann R (2005) Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia 19(6):984\u2013989. doi: 10.1038\/sj.leu.2403756","journal-title":"Leukemia"},{"issue":"18","key":"2314_CR28","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","volume":"29","author":"M Bjorkholm","year":"2011","unstructured":"Bjorkholm M, Ohm L, Eloranta S, Derolf A, Hultcrantz M, Sjoberg J, Andersson T, Hoglund M, Richter J, Landgren O, Kristinsson SY, Dickman PW (2011) Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 29(18):2514\u20132520. doi: 10.1200\/JCO.2011.34.7146","journal-title":"J Clin Oncol"},{"issue":"15S","key":"2314_CR29","doi-asserted-by":"crossref","first-page":"7088","DOI":"10.1200\/jco.2008.26.15_suppl.7088","volume":"26","author":"S Corm","year":"2008","unstructured":"Corm S, Micol JB, Leroyer A, Daudignon A, Preudhomme C, Poulain B, Bregman B, Oukessou A, Lai J, Facon T (2008) Kinetic of chronic myeloid leukemia (CML) prevalence in Northern France since the introduction of imatinib. J Clin Oncol (Suppl) 26(15S):7088","journal-title":"J Clin Oncol (Suppl)"},{"issue":"12","key":"2314_CR30","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","volume":"118","author":"X Huang","year":"2012","unstructured":"Huang X, Cortes J, Kantarjian H (2012) Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 118(12):3123\u20133127. doi: 10.1002\/cncr.26679","journal-title":"Cancer"},{"key":"2314_CR31","doi-asserted-by":"crossref","unstructured":"Ohm L, Lundqvist A, Dickman P, Hoglund M, Persson U, Stenke L, Steen Carlsson K, Bjorkholm M (2014) Real-world cost-effectiveness in chronic myeloid leukaemia: the price of success during four decades of development from non-targeted treatment to imatinib. Leuk Lymphoma 1\u201316. doi: 10.3109\/10428194.2014.953141","DOI":"10.3109\/10428194.2014.953141"},{"key":"2314_CR32","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1182\/blood.V15.3.313.313","volume":"15","author":"R Heyssel","year":"1960","unstructured":"Heyssel R, Brill AB, Woodbury LA, Nishimura ET, Ghose T, Hoshino T, Yamasaki M (1960) Leukemia in Hiroshima atomic bomb survivors. Blood 15:313\u2013331","journal-title":"Blood"},{"issue":"4","key":"2314_CR33","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.canep.2013.03.012","volume":"37","author":"JR Musselman","year":"2013","unstructured":"Musselman JR, Blair CK, Cerhan JR, Nguyen P, Hirsch B, Ross JA (2013) Risk of adult acute and chronic myeloid leukemia with cigarette smoking and cessation. Cancer Epidemiol 37(4):410\u2013416. doi: 10.1016\/j.canep.2013.03.012","journal-title":"Cancer Epidemiol"},{"issue":"7","key":"2314_CR34","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","volume":"103","author":"C Gambacorti-Passerini","year":"2011","unstructured":"Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, Nagler A, Della Casa CM, Morra E, Abruzzese E, D\u2019Emilio A, Stagno F, le Coutre P, Hurtado-Monroy R, Santini V, Martino B, Pane F, Piccin A, Giraldo P, Assouline S, Durosinmi MA, Leeksma O, Pogliani EM, Puttini M, Jang E, Reiffers J, Valsecchi MG, Kim DW (2011) Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 103(7):553\u2013561. doi: 10.1093\/jnci\/djr060","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"2314_CR35","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1634\/theoncologist.2010-0393","volume":"16","author":"D Pulte","year":"2011","unstructured":"Pulte D, Gondos A, Redaniel MT, Brenner H (2011) Survival of patients with chronic myelocytic leukemia: comparisons of estimates from clinical trial settings and population-based cancer registries. Oncologist 16(5):663\u2013671. doi: 10.1634\/theoncologist. 2010-0393","journal-title":"Oncologist"},{"issue":"14","key":"2314_CR36","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1002\/cncr.28106","volume":"119","author":"AM Brunner","year":"2013","unstructured":"Brunner AM, Campigotto F, Sadrzadeh H, Drapkin BJ, Chen YB, Neuberg DS, Fathi AT (2013) Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis. Cancer 119(14):2620\u20132629. doi: 10.1002\/cncr.28106","journal-title":"Cancer"},{"key":"2314_CR37","author":"BK Shah","year":"2013","unstructured":"Shah BK, Ghimire KB (2013) Chronic myeloid leukemia survival in older population in the United States. Leuk Lymphoma. doi: 10.3109\/10428194.2013.775435","journal-title":"Leuk Lymphoma"},{"key":"2314_CR38","doi-asserted-by":"crossref","unstructured":"Wiggins CL, Harlan LC, Nelson HE, Stevens JL, Willman CL, Libby EN, Hromas RA (2010) Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia. Am J Med 123(8):764 e761-769. doi: 10.1016\/j.amjmed.2010.03.018","DOI":"10.1016\/j.amjmed.2010.03.018"},{"issue":"7","key":"2314_CR39","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00277-014-2041-0","volume":"93","author":"U Proetel","year":"2014","unstructured":"Proetel U, Pletsch N, Lauseker M, Muller MC, Hanfstein B, Krause SW, Kalmanti L, Schreiber A, Heim D, Baerlocher GM, Hofmann WK, Lange E, Einsele H, Wernli M, Kremers S, Schlag R, Muller L, Hanel M, Link H, Hertenstein B, Pfirrman M, Hochhaus A, Hasford J, Hehlmann R, Saussele S, German Chronic Myeloid Leukemia Study G, Schweizerische Arbeitsgemeinschaft fur Klinische K (2014) Older patients with chronic myeloid leukemia (\u226565\u00a0years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. Ann Hematol 93(7):1167\u20131176. doi: 10.1007\/s00277-014-2041-0","journal-title":"Ann Hematol"},{"issue":"21","key":"2314_CR40","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1182\/blood-2010-12-324228","volume":"117","author":"G Gugliotta","year":"2011","unstructured":"Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A, Martino B, Pregno P, Rupoli S, Ferrero D, Gherlinzoni F, Montefusco E, Bocchia M, Tiribelli M, Pierri I, Grifoni F, Marzocchi G, Amabile M, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M, Rosti G (2011) Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood 117(21):5591\u20135599. doi: 10.1182\/blood-2010-12-324228","journal-title":"Blood"},{"issue":"7","key":"2314_CR41","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.leukres.2013.04.001","volume":"37","author":"M Breccia","year":"2013","unstructured":"Breccia M, Alimena G (2013) The role of comorbidities in chronic myeloid leukemia. Leuk Res 37(7):729\u2013730. doi: 10.1016\/j.leukres.2013.04.001","journal-title":"Leuk Res"},{"issue":"5","key":"2314_CR42","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40(5):373\u2013383","journal-title":"J Chron Dis"},{"key":"2314_CR43","unstructured":"Krauss MP, Lauseker M, Hehlmann R, Proetel U, Schreiber A, Kalmanti L, Hanfstein B, Einsele H, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Baerlocher GM, Heim D, Krause SW, Hofmann WK, Hasford J, Hochhaus A, Pfirrmann M, M\u00fcller MC (2013) Comorbidity, measured by the Charlson index, has no negative impact on remission in patients with chronic myeloid leukemia: results of the randomized CML-Study IV, vol 122. vol 21."},{"issue":"2","key":"2314_CR44","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1600-0609.2011.01637.x","volume":"87","author":"E Faber","year":"2011","unstructured":"Faber E, Muzik J, Koza V, Demeckova E, Voglova J, Demitrovicova L, Chudej J, Markuljak I, Cmunt E, Kozak T, Tothova E, Jarosova M, Dusek L, Indrak K (2011) Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000\u2014a report from the population-based CAMELIA Registry. Eur J Haematol 87(2):157\u2013168. doi: 10.1111\/j.1600-0609.2011.01637.x","journal-title":"Eur J Haematol"},{"issue":"16","key":"2314_CR45","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1182\/blood-2013-11-539742","volume":"123","author":"M Lauseker","year":"2014","unstructured":"Lauseker M, Hasford J, Pfirrmann M, Hehlmann R, German CMLSG (2014) The impact of health care settings on survival time of patients with chronic myeloid leukemia. Blood 123(16):2494\u20132496. doi: 10.1182\/blood-2013-11-539742","journal-title":"Blood"},{"issue":"25","key":"2314_CR46","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1182\/blood-2011-04-348755","volume":"118","author":"H Frederiksen","year":"2011","unstructured":"Frederiksen H, Farkas DK, Christiansen CF, Hasselbalch HC, Sorensen HT (2011) Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood 118(25):6515\u20136520. doi: 10.1182\/blood-2011-04-348755","journal-title":"Blood"},{"key":"2314_CR47","doi-asserted-by":"crossref","unstructured":"Gunnarsson N, Stenke L, H\u00f6glund M, Sandin F, Bj\u00f6rkholm M, Dreimane A, Lambe M, Markev\u00e4rn B, Olsson-Str\u00f6mberg U, Richer J, Wadenvik H, Wallvik J, Sj\u00e4lander A (2014) Second malignancies following treatment of chronic myeloid leukemia in the tyrosine kinase inhibitor era. ASH Annual Meeting Abstracts 2014, abstract no 154. Br. J. Haematol. doi: 10.1111\/bjh.13346","DOI":"10.1111\/bjh.13346"},{"issue":"9","key":"2314_CR48","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1093\/aje\/kwq262","volume":"172","author":"P Rebora","year":"2010","unstructured":"Rebora P, Czene K, Antolini L, Gambacorti Passerini C, Reilly M, Valsecchi MG (2010) Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study. Am J Epidemiol 172(9):1028\u20131033. doi: 10.1093\/aje\/kwq262","journal-title":"Am J Epidemiol"},{"issue":"3","key":"2314_CR49","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4149\/neo_2011_03_256","volume":"58","author":"J Voglova","year":"2011","unstructured":"Voglova J, Muzik J, Faber E, Zackova D, Klamova H, Steinerova K, Michalovicova Z, Demitrovicova L, Cmunt E, Novakova L, Tothova E, Belohlavkova P, Mayer J, Indrak K (2011) Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia. Neoplasma 58(3):256\u2013262","journal-title":"Neoplasma"},{"issue":"16","key":"2314_CR50","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1182\/blood-2011-06-362889","volume":"118","author":"D Verma","year":"2011","unstructured":"Verma D, Kantarjian H, Strom SS, Rios MB, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, O\u2019Brien S, Cortes J (2011) Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood 118(16):4353\u20134358. doi: 10.1182\/blood-2011-06-362889","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2314-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-015-2314-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2314-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T05:23:44Z","timestamp":1598851424000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-015-2314-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,27]]},"references-count":50,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["2314"],"URL":"https:\/\/doi.org\/10.1007\/s00277-015-2314-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,27]]}}}